Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $43 | $26 | $31 |
| % Growth | -100% | 65.3% | -17.6% | – |
| Cost of Goods Sold | $0 | $42 | $3 | $2 |
| Gross Profit | $0 | $1 | $23 | $29 |
| % Margin | – | 2.4% | 89.3% | 92.5% |
| R&D Expenses | $8 | $42 | $53 | $67 |
| G&A Expenses | $6 | $17 | $16 | $17 |
| SG&A Expenses | $6 | $17 | $16 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $14 | -$8 | -$4 |
| Operating Expenses | $14 | $73 | $61 | $80 |
| Operating Income | $0 | -$30 | -$43 | -$52 |
| % Margin | – | -69.5% | -167.8% | -165% |
| Other Income/Exp. Net | $0 | $5 | $10 | $6 |
| Pre-Tax Income | -$17 | -$25 | -$33 | -$46 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$25 | -$31 | -$43 |
| % Margin | – | -57.3% | -120.7% | -138% |
| EPS | -7.83 | -21.8 | -33.71 | -53.75 |
| % Growth | 64.1% | 35.3% | 37.3% | – |
| EPS Diluted | -7.83 | -21.8 | -33.71 | -53.75 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $1 | $0 |
| Interest Expense | -$4 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $3 | $2 |
| EBITDA | $0 | -$23 | -$33 | -$46 |
| % Margin | – | -53.2% | -125.6% | -145.7% |